EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials

Ismaila Ajayi Yusuf iD, Olurotimi J Badero iD, Alozie Ihesiulo iD, Micah Nnabuko Okwah iD, Abieyuwa Oshodin, Emmanuella Asikong iD

PLOS One · 03.06.2026 · 21 (6) · e0349932

DOI: 10.1371/journal.pone.0349932 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS One, online erschienen am 03.06.2026. Verfasst von Ismaila Ajayi Yusuf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aldosterone synthase inhibitors (ASIs) have emerged as a mechanistically targeted strategy for resistant and uncontrolled hypertension; however, no head-to-head trials exist, and comparative efficacy and safety remain uncertain. We compared their efficacy and safety using network and pairwise meta-analysis of randomized trials.

Methods

This systematic review and meta-analysis adhered to the PRISMA guidelines. PubMed/MEDLINE, Scopus, Embase, ClinicalTrials.gov, and Cochrane Library were searched from inception to January 14, 2026, for randomized trials evaluating ASIs versus placebo or standard care. A frequentist random-effects network meta-analysis assessed systolic (SBP) and diastolic blood pressure (DBP). Dichotomous safety outcomes were pooled using Hartung–Knapp random-effects models. Network consistency was evaluated using design-by-treatment interaction modeling. Prespecified subgroup analyses stratified outcomes by hypertension phenotype (resistant vs uncontrolled).

Results

Across 7 RCTs (n = 2,828), all ASIs significantly reduced SBP versus placebo: baxdrostat −8.63 mmHg (95% CI −10.84 to −6.42), lorundrostat −7.47 mmHg (95% CI −9.54 to −5.40), and LCI699/osilodrostat −5.63 mmHg (95% CI −9.15 to −2.12), with no significant indirect differences between agents. In resistant hypertension, lorundrostat (−9.00 mmHg; 95% CI −13.19 to −4.81) and baxdrostat (−8.77 mmHg; 95% CI −10.50 to −7.05) demonstrated pronounced reductions. In uncontrolled hypertension, LCI699/osilodrostat showed the largest point estimate (−10.55 mmHg; 95% CI −16.49 to −4.61), though this derives from a single early-phase trial and requires cautious interpretation. DBP reductions were significant for baxdrostat (−3.23 mmHg; 95% CI −4.73 to −1.73) and lorundrostat (−3.60 mmHg; 95% CI −5.43 to −1.77). Hypotension (RR 2.67), hyperkalemia (RR 7.94), and hyponatremia (RR 2.07) were significantly increased; serious adverse events, discontinuation, and network inconsistency were not detected.

Conclusions

ASIs provide clinically meaningful BP reduction across both hypertension phenotypes; however, short-term use is associated with hypotension and electrolyte disturbances, necessitating careful monitoring. Phenotype-specific efficacy and long-term safety require validation in outcome-driven trials. Systematic Review Registration: PROSPERO CRD420251266257

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCytochrome P-450 CYP11B2Antihypertensive AgentsHumansRandomized Controlled Trials as TopicPhenotypeBlood PressureDrug Resistance

Substanzen

Cytochrome P-450 CYP11B2Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, United States of America.
  • Division of CardioNephrology, Cardiac Renal & Vascular Associates, Jackson, Mississippi, United States of America.
  • Department of Medicine, University of Calabar, Calabar, Nigeria.
  • Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Department of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria.

ORCID-Profile: Ismaila Ajayi Yusuf, Olurotimi J Badero, Alozie Ihesiulo, Micah Nnabuko Okwah, Emmanuella Asikong

Zitieren

APA

Yusuf, I. A., Badero, O. J., Ihesiulo, A., Okwah, M. N., Oshodin, A., & Asikong, E. (2026). Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials. PLOS One, 21(6), e0349932. https://doi.org/10.1371/journal.pone.0349932

Vancouver

Yusuf IA, Badero OJ, Ihesiulo A, Okwah MN, Oshodin A, Asikong E. Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials. PLOS One. 2026;21(6):e0349932. doi:10.1371/journal.pone.0349932

BibTeX
@article{Yusuf2026,
  author = {Yusuf, Ismaila Ajayi and Badero, Olurotimi J and Ihesiulo, Alozie and Okwah, Micah Nnabuko and Oshodin, Abieyuwa and Asikong, Emmanuella},
  title = {Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0349932},
  doi = {10.1371/journal.pone.0349932}
}
Kostenlos starten →